Four-year maintenance treatment with adalimumab in patients with moderately to severely active ulcerative colitis: Data from ULTRA 1, 2, and 3.

Colombel, Jean-Frederic; J Sandborn, William; Ghosh, Subrata; C Wolf, Douglas; Panaccione, Remo; Feagan, Brian; Reinisch, Walter; M Robinson, Anne; Lazar, Andreas; Kron, Martina; Huang, Bidan; Skup, Martha; B Thakkar, Roopal

doi:10.1038/ajg.2014.242

Public

Four-year maintenance treatment with adalimumab in patients with moderately to severely active ulcerative colitis: Data from ULTRA 1, 2, and 3.

Shared by NobleBlocks on Nov 1, 2014 • 12:00 AM UTC

Authors:

Jean-Frederic Colombel

William J Sandborn

Subrata Ghosh

Abstract

OBJECTIVES: The safety and efficacy of adalimumab for patients with moderately to severely active ulcerative colitis (UC) has been reported up to week 52 from the placebo-controlled trials ULTRA (Ulcerative Colitis Long-Term Remission and Maintenance with Adalimumab) 1 and 2. Up to 4 years of data f...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!